Bristol-Myers Squibb Company Ce (CELG-RI) P/E Ratio History
Fairly ValuedTrading at 0.0x, near 5Y avg of 0.0x · 55th percentile · In line with own history · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, Bristol-Myers Squibb Company Ce (CELG-RI) trades at a price-to-earnings ratio of 0.0x, with a stock price of $0.09 and trailing twelve-month earnings per share of $3.55.
The current P/E is roughly in line with its 5-year average of 0.0x. Over the past five years, CELG-RI's P/E has ranged from a low of 0.0x to a high of 0.0x, placing the current valuation at the 55th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, CELG-RI trades at a 100% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, CELG-RI trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CELG-RI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CELG-RI Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CELG-RI P/E vs Peers
Large diversified branded pharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $120B | 17.0 | - | +178% | |
| $320B | 17.8 | 0.84 | +8% | |
| $139B | 17.9 | - | -4% | |
| $296B | 29.2 | 1.34 | +191% | |
| $1.2T | 53.6 | 1.86 | +96% | |
| $449B | 107.3 | - | -1% | |
| $157B | 18.6 | 0.14Best | +1684%Best | |
| $32B | 24.5 | - | -21% | |
| $66B | 15.2Lowest | 2.41 | +8% | |
| $127B | 32.6 | 3.94 | +837% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CELG-RI Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $0.12 | $3.56 | 0.0x | +24% |
| FY2025 Q4 | Dec 31 2025 | $0.06 | $3.45 | 0.0x | -31% |
| FY2025 Q3 | - | $0.03 | $2.96 | 0.0x | -57% |
| FY2025 Q2 | Jun 30 2025 | $0.03 | $2.48 | 0.0x | -62% |
| FY2025 Q1 | Mar 31 2025 | $0.05 | $2.67 | 0.0x | -29% |
| FY2023 Q4 | Dec 31 2023 | $0.09 | $3.86 | 0.0x | -12% |
| FY2023 Q3 | Sep 30 2023 | $0.10 | $3.94 | 0.0x | -9% |
| FY2023 Q2 | Jun 30 2023 | $0.11 | $3.76 | 0.0x | +11% |
| FY2023 Q1 | Mar 31 2023 | $0.13 | $3.43 | 0.0x | +39% |
| FY2022 Q4 | Dec 31 2022 | $0.12 | $2.95 | 0.0x | +52% |
| FY2022 Q3 | Sep 30 2022 | $0.14 | $3.07 | 0.0x | +73% |
Average P/E for displayed period: 0.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CELG-RI — Frequently Asked Questions
Quick answers to the most common questions about buying CELG-RI stock.
What is CELG-RI's P/E ratio?
Bristol-Myers Squibb Company Ce (CELG-RI) trailing twelve-month P/E ratio is 0.0x, based on TTM diluted EPS of $3.55. The 5-year average P/E is 0.0x and the historical range spans 0.0x to 0.0x.
Is CELG-RI stock overvalued or undervalued?
CELG-RI current P/E: 0.0x. 5-year average P/E: 0.0x. Percentile: 55th.
Is CELG-RI stock expensive?
CELG-RI is fairly valued relative to its own history. The current P/E of 0.0x is near the 5-year average of 0.0x (55th percentile of historical range).
What is CELG-RI's historical P/E range?
Over the past 5 years, CELG-RI's P/E ratio has ranged from 0.0x to 0.0x, with a median of 0.0x and an average of 0.0x. The current P/E of 0.0x places the stock at the 55th percentile of this range. Full historical data spans 2022–2026.
How does CELG-RI's P/E compare to the S&P 500?
CELG-RI current P/E: 0.0x. S&P 500 median P/E: 25.1x.
How does CELG-RI's valuation compare to Healthcare peers?
Bristol-Myers Squibb Company Ce P/E of 0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is CELG-RI's PEG ratio?
CELG-RI PEG ratio is N/A, based on a P/E of 0.0x and EPS growth of 178.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CELG-RI's earnings yield?
CELG-RI earnings yield is 100.00%, the inverse of its 0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.